| 101 |
17180388 | The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. | 2007 May |
6 |
| 102 |
17429432 | Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. | 2007 Jul |
1 |
| 103 |
17495881 | Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. | 2007 Jul |
1 |
| 104 |
16890580 | Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. | 2006 Aug |
2 |
| 105 |
15805252 | The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. | 2005 Apr 1 |
1 |
| 106 |
15902298 | Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. | 2005 Jul |
6 |
| 107 |
15918555 | [Anticancer drugs and ABC transporters]. | 2005 May |
1 |
| 108 |
15963852 | RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. | 2005 Jul |
5 |
| 109 |
15970668 | Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. | 2005 Jul |
8 |
| 110 |
16157201 | Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. | 2005 Oct 1 |
3 |
| 111 |
16620554 | [Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line]. | 2005 Nov |
2 |
| 112 |
14724652 | P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. | 2004 Mar |
8 |
| 113 |
15250677 | Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. | 2004 |
1 |
| 114 |
15251980 | Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. | 2004 Nov 1 |
2 |
| 115 |
15308010 | [Establishment of an imatinib resistant cell line K562/G01 and its characterization]. | 2004 Jun |
1 |
| 116 |
15315971 | Active transport of imatinib into and out of cells: implications for drug resistance. | 2004 Dec 1 |
1 |
| 117 |
15611623 | Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. | 2004 Dec |
2 |
| 118 |
12609962 | MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. | 2003 Mar 15 |
2 |
| 119 |
12824882 | Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. | 2003 Jun |
7 |
| 120 |
12869489 | Functional consequence of MDR1 expression on imatinib intracellular concentrations. | 2003 Aug 1 |
1 |
| 121 |
12963124 | Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line. | 2003 Sep 10 |
4 |
| 122 |
12975485 | Interaction of imatinib mesilate with human P-glycoprotein. | 2003 Nov |
10 |
| 123 |
14706143 | [The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells]. | 2003 Dec |
3 |